Picture of Sinovac Biotech logo

SVA Sinovac Biotech Income Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareMicro Cap

Annual income statement for Sinovac Biotech, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

2018
December 31st
2019
December 31st
2020
December 31st
2021
December 31st
2022
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:20-F20-F20-F20-F20-F
Standards:
USG
USG
USG
USG
USG
Status:FinalFinalFinalFinalFinal
Revenue
Total Revenue23024651119,3751,493
Cost of Revenue
Gross Profit20521444318,303808
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses1841772951,8221,959
Operating Profit45.368.621617,553-466
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes46.670.821717,56325.2
Provision for Income Taxes
Net Income After Taxes36.165.218514,45988.1
Minority Interest
Net Income Before Extraordinary Items
Extraordinary Items
Net Income21.844.91108,467114
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income21.839.81048,461108
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS0.3360.3650.91974.20.975